<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Poliovirus vaccine (inactivated) (IPV): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Poliovirus vaccine (inactivated) (IPV): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Poliovirus vaccine (inactivated) (IPV): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11884" href="/d/html/11884.html" rel="external">see "Poliovirus vaccine (inactivated) (IPV): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12967" href="/d/html/12967.html" rel="external">see "Poliovirus vaccine (inactivated) (IPV): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F211024"><span class="drugH1">Brand Names: US</span>
<ul>
<li>IPOL</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52914133"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Imovax Polio</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F211033"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vaccine;</li>
<li>
                        Vaccine, Inactivated (Viral)</li></ul></div>
<div class="block doa drugH1Div" id="F211026"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, SUBQ:</b> Administer 0.5 mL per dose for a total of 3 doses given as follows: Two 0.5 mL doses administered at a 1- to 2-month interval, followed by a third dose 6 to 12 months later. If &lt;3 months, but at least 2 months are available before protection is needed, 3 doses may be administered at least 1 month apart. If administration must be completed within 1 to 2 months, give 2 doses at least 1 month apart. If &lt;1 month is available, give 1 dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Incomplete vaccination:</i>
<b>IM, SUBQ:</b> Adults at an increased risk of exposure and who have had at least 1 previous dose of trivalent OPV (tOPV), &lt;3 doses of IPV, or a combination of tOPV and IPV equaling &lt;3 doses, administer at least one 0.5 mL dose of IPV. Additional doses to complete the series should be given if time permits.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Booster dose: IM, SUBQ:</b> 0.5 mL as a single dose for persons at increased risk of exposure.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991147"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988488"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F211027"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F211029"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12967" href="/d/html/12967.html" rel="external">see "Poliovirus vaccine (inactivated) (IPV): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization: Note: </b>Use of the minimum age and minimum intervals (4 weeks) during the first 6 months of life should only be done when the vaccine recipient is at risk for imminent exposure to circulating poliovirus (shorter intervals and earlier start dates may lead to lower seroconversion) (CDC/ACIP 2009). Refer to CDC/ACIP for guidance on schedules and interval for individuals who received polio vaccination(s) (including oral formulation) outside of the United States (CDC/ACIP [Marin 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children 6 weeks to 47 months: IM, SUBQ: 0.5 mL per dose for a total of 3 doses administered as follows: 2 months, 4 months, and 6 to 18 months of age.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3186cf6-f751-4742-9832-a3acba1abdd9">Booster immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Booster immunization:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to 6 years: IM, SUBQ: 0.5 mL as a single dose administered at least 6 months after the previous dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years at increased risk of exposure to poliovirus: IM, SUBQ: 0.5 mL as a single dose (ACIP/CDC [Wodi 2023]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="030231b8-f8a7-4a85-8830-e75f8b3f4505">Catch-up immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Catch-up immunization: </b>Infants, Children, and Adolescents 4 months to 18 years: <b>Note:</b> Do not restart the series if doses have been given (OPV and/or IPV); refer to current immunization guidelines for specific schedule and timing of dose based on patient age and date and number of previous doses. IM, SUBQ: 0.5 mL per dose for a total of 1 to 4 doses.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51153899"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51153900"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F211007"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for infants and children. Percentages noted with concomitant administration of DTP or DTaP vaccine and observed within 48 hours of injection, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (1% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Swelling at injection site (≤11%), tenderness at injection site (1% to 29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (4% to 61%), irritability (7% to 65%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Excessive crying (1%; reported within 72 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&gt;39°C: ≤4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, hypersensitivity reaction, type 1 hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Rash at injection site, residual mass at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, drowsiness, febrile seizure, headache, paresthesia, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p></div>
<div class="block coi drugH1Div" id="F211018"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to any component of the vaccine, including 2-phenoxyethanol, formaldehyde, neomycin, streptomycin and polymyxin B; anaphylaxis or anaphylactic shock occurring within 24 hours of administration of 1 dose of vaccine; acute, febrile illness (excluding minor illness with or without low-grade fever).</p></div>
<div class="block war drugH1Div" id="F211004"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis, tendinopathy) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); more often reported in adolescents and young adults and typically within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Polio infection: Patients with prior clinical poliomyelitis or incomplete vaccination with oral poliovirus vaccine (OPV) may receive inactivated poliovirus vaccine (IPV).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune globulin: Immune response may be decreased in patients receiving immune globulin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual components. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific product is unavailable (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Consider deferring vaccination during periods of severe immunosuppression; may have a reduced response to vaccination. According to the manufacturer, patients with HIV infection, severe combined immunodeficiency, hypogammaglobulinemia, agammaglobulinemia, or altered immunity (due to corticosteroids, alkylating agents, antimetabolites, or radiation) may receive inactivated poliovirus vaccine (IPV). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines. Inactivated vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2021]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use of the minimum age and minimum intervals during the first 6 months of life should only be done when the vaccine recipient is at risk for imminent exposure to circulating poliovirus (shorter intervals and earlier start dates may lead to lower seroconversion). Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• 2-phenoxyethanol: Products may contain 2-phenoxyethanol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Calf serum protein: Products may contain calf serum protein.</p>
<p style="text-indent:-2em;margin-left:4em;">• Formaldehyde: Products may contain formaldehyde.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neomycin: Products may contain neomycin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polymyxin B: Products may contain polymyxin B.</p>
<p style="text-indent:-2em;margin-left:4em;">• Streptomycin: Products may contain streptomycin.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2021]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the annual ACIP Recommended Immunization Schedules (refer to CDC schedule for detailed information). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2021]).</p></div>
<div class="block foc drugH1Div" id="F211013"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, suspension:</p>
<p style="text-indent:-2em;margin-left:4em;">IPOL: Type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL, 5 mL) [contains 2-phenoxyethanol, formaldehyde, calf serum protein, neomycin (may have trace amounts), streptomycin (may have trace amounts), and polymyxin B (may have trace amounts)]</p></div>
<div class="block geq drugH1Div" id="F211001"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F211016"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IM, SUBQ:</b> For IM or SUBQ administration in the deltoid area; do not administer IV. Use proper injection technique for IM injection into the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, patients should be vaccinated while seated or lying down (ACIP [Kroger 2021]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded. Imovax Polio (Canadian product) should be shaken well before use.</p>
<p style="text-indent:0em;margin-top:2em;">For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) should be used for the vaccination and firm pressure on the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2021]).</p></div>
<div class="block admp drugH1Div" id="F52613612"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IM, SUBQ: </b>Administer IM or SUBQ into midlateral aspect of the thigh in infants and small children; administer in the deltoid area in older children and adolescents; not for IV administration. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2021]). To prevent syncope-related injuries, adolescents should be vaccinated while seated or lying down (ACIP [Kroger 2021]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:0em;margin-top:2em;">For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) should be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2021]).</p></div>
<div class="block meg drugH1Div" id="F25734135"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">In the U.S, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Fipv.html&amp;token=Jo%2BTJVXtdtuhdib4J4tH0wIdFfAoQY6fCoIuVJr%2BFoXRX%2F80yLOyozFsfsL3%2BMw3XHD7ANvZUg1OBus0VA9g9w%3D%3D&amp;TOPIC_ID=9787" target="_blank">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/ipv.html</a>.</p></div>
<div class="block use drugH1Div" id="F211014"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Poliovirus prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Active immunization for prevention of poliomyelitis caused by poliovirus types 1, 2, and 3 in the following persons:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>US labeling:</i> Infants (≥6 weeks), children, adolescents, and adults</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Canadian labeling:</i> Infants (≥2 months), children, adolescents, and adults</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">The Advisory Committee on Immunization Practices (ACIP) and Canada's National Advisory Committee on Immunization (NACI) recommend routine vaccination for the following:</p>
<p style="text-indent:-2em;margin-left:6em;">• All infants and children (CDC/ACIP 2009; PHAC 2015)</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">Routine vaccination of adults in the United States and Canada is generally not recommended. Adults with previous wild poliovirus disease, who have never been vaccinated, or those who are incompletely vaccinated may receive inactivated poliovirus vaccine if they fall into one of the following categories (CDC/ACIP [Prevots 2000]; PHAC 2015):</p>
<p style="text-indent:-2em;margin-left:6em;">• Travelers to regions or countries where poliomyelitis is endemic or epidemic</p>
<p style="text-indent:-2em;margin-left:6em;">• Healthcare workers in close contact with patients who may be excreting poliovirus</p>
<p style="text-indent:-2em;margin-left:6em;">• Laboratory workers handling specimens that may contain poliovirus</p>
<p style="text-indent:-2em;margin-left:6em;">• Members of communities or specific population groups with diseases caused by wild poliovirus</p>
<p style="text-indent:-2em;margin-left:6em;">• Incompletely vaccinated or unvaccinated adults in a household or with other close contact with children receiving oral poliovirus (may be at increased risk of vaccine associated paralytic poliomyelitis)</p></div>
<div class="block mst drugH1Div" id="F12705163"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">IPV (inactivated poliovirus vaccine) may be confused with HPV (human papilloma virus vaccine)</p>
<p style="text-indent:-2em;margin-left:4em;">IPV (inactivated poliovirus vaccine) may be confused with PPD (purified protein derivative tuberculin test).</p>
<p style="text-indent:-2em;margin-left:4em;">IPV (inactivated poliovirus vaccine), a trivalent product, may be confused with OPV (oral poliovirus vaccine [live/bivalent]), which is no longer licensed in the United States, but still used in some other countries.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Poliovirus vaccine (inactivated) may be confused with tuberculin products. Medication errors have occurred when poliovirus vaccine (IPV) has been inadvertently administered instead of tuberculin skin tests (PPD). Both of these products are refrigerated and often stored in close proximity to each other.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299896"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F211008"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of cladribine when possible. Patients vaccinated less than 14 days before initiating or during cladribine should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to methotrexate initiation, if possible. If patients are vaccinated less than 14 days prior to or during methotrexate therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F2983218"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted with the inactivated poliovirus vaccine (IPV).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnancy may be a risk factor for paralytic disease following poliomyelitis infection (CDC/ACIP [Prevots 2000]). Patients previously diagnosed with polio may have an increased risk of adverse pregnancy outcomes (Veiby 2007).</p>
<p style="text-indent:0em;margin-top:2em;">Although vaccination of pregnant patients may be avoided on theoretical grounds, previously unvaccinated pregnant patients at increased risk for infection may be administered IPV; this includes pregnant patients who are traveling to countries where polio is epidemic or endemic, those in communities with disease caused by wild polioviruses, laboratory workers handling poliovirus specimens, health care personnel in close contact with infected patients, and unvaccinated persons whose children may be receiving an oral poliovirus vaccine (ACIP [Kroger 2021]; CDC/ACIP [Prevots 2000]).</p></div>
<div class="block brc drugH1Div" id="F12674687"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if the components of this vaccine are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding patients may be administered IPV (CDC/ACIP [Prevots 2000]). Administration does not affect the safety of breastfeeding for the mother or the infant. Breastfeeding infants should be vaccinated according to recommended schedules (ACIP [Kroger 2021]).</p></div>
<div class="block mop drugH1Div" id="F7676664"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2021]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F25318339"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As an inactivated virus vaccine, poliovirus vaccine induces active immunity against poliovirus types 1, 2, and 3 infection</p></div>
<div class="block phk drugH1Div" id="F57997004"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: In the United States, ≥95% of infants and children 2 to 18 months of age who received 2 doses of the vaccine developed seroconversion to all 3 serotypes. A full 3-dose primary regimen is needed for optimal immunity.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Immunity typically persists for decades or possibly lifelong after a 3-dose primary series (WHO 2022).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038772"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Poliorix</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Imovax polio</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Imovax polio</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Poliorix</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Poliorix</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Inactivated poliomyelitis vaccine made from sabin strains (vero cell) | Poliomyelitis vaccine (vero cell), inactivated, sabin strains</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">IPV Virelon</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Imovax polio</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Poliorix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Poliorix</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Imovax polio</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Polprotec</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Poliorix</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Poliorix</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Imovax polio</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Poliorix</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Polprotec</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Poliorix</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Poliorix</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ipol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Poliorix</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Polprotec</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Imovax polio</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16456525">
<a name="16456525"></a>Centers for Disease Control and Prevention (CDC), “Imported Vaccine-Associated Paralytic Poliomyelitis -- United States,” <i>MMWR Morb Mortal Wkly Rep</i>, 2005, 55(4):97-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-ipv-drug-information/abstract-text/16456525/pubmed" id="16456525" target="_blank">16456525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19661857">
<a name="19661857"></a>Centers for Disease Control and Prevention (CDC). Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. <i>MMWR Morb Mortal Wkly Rep</i>. 2009;58(30):829-830.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-ipv-drug-information/abstract-text/19661857/pubmed" id="19661857" target="_blank">19661857</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Vaccination guidance during a pandemic. Updated October 20, 2020. Available at <a href="https://www.cdc.gov/vaccines/pandemic-guidance/index.html" target="_blank">https://www.cdc.gov/vaccines/pandemic-guidance/index.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303‐306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-ipv-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc (2003)</i>. 2013;53(1):102‐103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-ipv-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Imovax Polio (inactivated poliomyelitis vaccine) [product monograph]. Toronto, Ontario, Canada: Sanofi Pasteur Limited; April 2011.</div>
</li>
<li>
<div class="reference">
                  IPOL (poliovirus vaccine inactivated) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; May 2020.</div>
</li>
<li>
<div class="reference">
                  Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081056">
<a name="28081056"></a>Marin M, Patel M, Oberste S, Pallansch MA. Guidance for assessment of poliovirus vaccination status and vaccination of children who have received poliovirus vaccine outside the United States. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(1):23-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-ipv-drug-information/abstract-text/28081056/pubmed" id="28081056" target="_blank">28081056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15580728">
<a name="15580728"></a>Prevots DR, Burr RK, Sutter RW, Murphy TV; Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2000;49(RR-5):1-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-ipv-drug-information/abstract-text/15580728/pubmed" id="15580728" target="_blank">15580728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al, “Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,” <i>Lancet</i>, 2009, 374(9698):1339-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-ipv-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PHAC.1">
<a name="PHAC.1"></a>Public Health Agency of Canada (PHAC). Poliomyelitis vaccines: Canadian immunization guide. <a href="https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-17-poliomyelitis-vaccine.html" target="_blank">https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-17-poliomyelitis-vaccine.html</a> Updated January 2015. Accessed January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-ipv-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17395208">
<a name="17395208"></a>Veiby G, Daltveit AK, Gilhus NE. Pregnancy, delivery and perinatal outcome in female survivors of polio. <i>J Neurol Sci</i>. 2007;258(1-2):27-32. doi:10.1016/j.jns.2007.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-ipv-drug-information/abstract-text/17395208/pubmed" id="17395208" target="_blank">17395208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36757872">
<a name="36757872"></a>Wodi AP, Murthy N, McNally V, Cineas S, Ault K. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2023. <i>MMWR Morb Mortal Wkly Rep</i>. 2023;72(6):137-140. doi:10.15585/mmwr.mm7206a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-ipv-drug-information/abstract-text/36757872/pubmed" id="36757872" target="_blank">36757872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Published March 26, 2020. Available at https://apps.who.int/iris/handle/10665/331590
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Polio vaccines: WHO position paper - June 2022. <i>Weekly Epidemiological Record. </i>2022;97(25):277-300. Available at https://www.who.int/publications/i/item/WHO-WER9725-277-300
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 9787 Version 166.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
